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Abstract
Objective—To determine whether maternal body mass index (BMI) influences the beneficial 
effects of diabetes treatment in women with gestational diabetes (GDM).
Study Design—Secondary analysis of a multicenter randomized treatment trial of women with 
GDM. Outcomes of interest were elevated umbilical cord c-peptide levels (>90th percentile 1.77 
ng/mL), LGA birth weight (>90th percentile), and neonatal fat mass (g). Women were grouped 
into five BMI categories adapted from the WHO International Classification of normal, 
overweight, and obese adults. Outcomes were analyzed according to treatment group assignment.
Results—A total of 958 women were enrolled (485 treated and 473 controls). Maternal BMI at 
enrollment was not related to umbilical cord c-peptide levels. However, treatment of women in the 
overweight, Class I, and Class II obese categories was associated with a reduction in both LGA 
birth weight and neonatal fat mass. Neither measure of excess fetal growth was reduced with 
treatment in normal weight (BMI <25) or Class III (BMI ≥ 40) obese women.
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Conclusion—There was a beneficial effect of treatment on fetal growth in women with mild 
GDM who were overweight or Class I and II obese. These effects were not apparent for normal 
weight and very obese women.
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Introduction
In women identified with gestational diabetes (GDM), risk of excessive fetal growth is 
commonly attributed to maternal hyperglycemia. However, maternal obesity and weight 
gain during pregnancy also have a significant impact on the development of overgrown 
infants.1–4 Recent analyses of the results of the Hyperglycemia and Adverse Pregnancy 
Outcomes (HAPO) study demonstrate that both maternal body mass index (BMI) and 
glucose levels have strong independent associations with delivery of large for gestational 
age (LGA) infants.5 Neonatal fat mass and umbilical cord serum c-peptide, a surrogate for 
fetal hyperinsulinemia, are also increased in offspring of women with glucose intolerance 
identified during pregnancy.6,7 A secondary analysis of the HAPO study as well as other 
studies have found that neonatal fat mass, fetal hyperinsulinemia, and neonatal 
hypoglycemia are positively related to maternal size after adjustment for maternal 
glycemia.5,8,9,10
In the original HAPO observational study, LGA birth weight, umbilical cord serum c-
peptide, and neonatal fat mass were all increased in a continuous fashion with maternal 
glucose values. This was true even at maternal glucose levels below thresholds typically 
used for diagnosis of diabetes during pregnancy.7, 11 Both the Australian Carbohydrate 
Intolerance Study (ACHOIS) and the Eunice Kennedy Shriver NICHD Maternal Fetal 
Medicine Units (MFMU) Network trial have established that treatment of women with mild 
degrees of hyperglycemia during pregnancy results in fewer large infants and consequent 
traumatic delivery. 12, 13 Taken together, these findings have led to the proposal of new 
thresholds for the diagnosis of GDM by the International Association of Diabetes and 
Pregnancy Study Groups (IADPSG).11, 14 It is estimated that these new thresholds will 
result in a dramatic increase in the number of pregnant women identified with mild GDM. In 
this secondary analysis of the MFMU Network trial, we sought to determine whether 
maternal BMI might alter the impact of therapy on fetal growth in women with mild 
GDM.12,13
Materials and Methods
This is a secondary analysis of a multi-center randomized clinical trial of treatment in 
women with mild GDM.13 Women with a 50-gram glucose screen administered between 24 
and 30 weeks 6 days gestation and serum glucose value between 135 and 200 mg per 
deciliter were eligible for a 3-hour oral glucose tolerance test. Mild GDM was defined as a 
fasting serum glucose value less than 95 mg/dl with two or more glucose measurements that 
met or exceeded established thresholds after a 100-gram oral glucose load: 1 hour ≥ 180 
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mg/dl; 2-hour ≥ 155 mg/dl; 3-hour ≥ 140 mg/dl.15 Women were randomized to treatment 
versus control group at each clinical center. Treated women received formal nutritional 
counseling and diet therapy. They also performed daily self-monitoring of their blood 
glucose including fasting and 2 hour postprandial measurements. Insulin was prescribed if 
the majority of fasting or postprandial values met or exceeded 95 mg% and 120 mg% 
respectively. Control women received usual prenatal care.
For this analysis, all women were grouped into five BMI (kg/m2) categories adapted from 
the WHO International Classification of normal, overweight, and obese adults. Normal 
weight women were those with a BMI of less than 25 kg/m2 at enrollment. Overweight 
women had a BMI from 25.0 to 29.9 kg/m2 and obese women with a BMI greater than or 
equal to 30 kg/m2 were subcategorized into three groups. Those with a BMI of 30.0 to 34.9 
kg/m2 were classified as Class I obese; those with a BMI of 35.0 to 39.9 kg/m2 were 
identified as Class II obese; and those with a BMI greater than or equal to 40 kg/m2 were 
identified as Class III or morbidly obese. Outcomes of interest for this secondary analysis 
were LGA birth weight, umbilical cord serum c-peptide levels, and neonatal fat mass. LGA 
birth weight was defined as birth weight above the 90th percentile for gestational age 
according to established national thresholds.16 Umbilical cord serum c-peptide was 
determined at a central laboratory. Fetal hyperinsulinemia was defined as cord c-peptide 
level greater than 1.77 ng/mL (95th percentile from an unselected obstetrical population of 
women in the Maternal-Fetal Medicine Units (MFMU) Network of the Eunice Kennedy 
Shriver National Institute of Child Health and Human Development). Shortly after birth, 
trained research personnel measured the infant’s length, head and upper mid-arm 
circumferences, and flank skinfold. Neonatal fat mass was calculated according to the 
technique described by Catalano and colleagues.17 Outcomes were analyzed according to 
treatment group assignment and BMI category.
Statistical analysis included Chi square or Fisher’s exact test for categorical variables, where 
appropriate, and the Wilcoxon Rank Sum test for continuous variables. A stratified analysis 
was used to examine the association between treatment group and each outcome of interest, 
stratified by BMI category. Statistical analysis was conducted with SAS software (SAS 
Institute, Cary, NC). A nominal two-sided P value less than 0.05 was considered to indicate 
statistical significance and no adjustments were made for multiple comparisons.
Results
Between October 2002 and November 2007, 958 women were identified with mild GDM at 
16 clinical centers and randomized to either treatment (n=485) or usual prenatal care 
(n=473).13 Shown in Table 1 are the baseline maternal characteristics of all women enrolled 
in the randomized trial according to treatment group. Eighty-five percent of women with 
mild GDM were either overweight or obese. Moreover, almost half were obese at the time of 
enrollment with 39 (4%) categorized as morbidly obese. There were no significant 
differences in demographic variables, oral glucose tolerance test results, or BMI category 
between the 485 treated and the 473 control women.
Casey et al. Page 3






















LGA birth weight, neonatal fat mass, and umbilical cord serum c-peptide levels were 
evaluated according to maternal BMI category and treatment group. The beneficial effects of 
treatment on the percent of women delivering an LGA birth weight infant are depicted in 
Figure 1. There were significant reductions in LGA birth weight in treated women with a 
BMI between 25 and 40 kg/m2 at enrollment. For example, 13 (9%) of the Class I obese 
women who received formal nutritional counseling and diet therapy delivered an overgrown 
infant compared to 29 (20%) of those who received routine prenatal care (P = .005). 
However, in women categorized as normal weight (n= 143) or in those who were morbidly 
obese (n=39), the beneficial treatment effect on excessive neonatal size was no longer 
evident. Likewise, as shown in Figure 2, women in the lowest (< 25 kg/m2) or highest (≥ 40 
kg/m2) BMI categories delivered infants with similar neonatal fat mass regardless of 
treatment assignment. Treated normal weight women delivered infants whose mean fat mass 
was calculated to be 385 ± 139 g compared to 336 ± 180 g in normal weight women who 
received routine care. In contrast, neonatal fat mass was significantly reduced with diet 
therapy and routine glucose monitoring in women with a BMI between 25–40 kg/m2. 
Overweight treated women delivered infants with a mean fat mass of 404 ± 189 g compared 
to 455 ± 210 g for women who received routine care. Umbilical cord serum c-peptide was 
elevated in 20 percent of the entire cohort. However, consideration of maternal BMI at 
enrollment did not modify the small but statistically insignificant treatment effect previously 
reported from this randomized trial (P = 0.16, data not shown).13
Discussion
The most noteworthy finding in this secondary analysis of a large multicenter randomized 
treatment trial of women with mild GDM is that the benefits of treatment concerning fetal 
overgrowth varies by maternal BMI at enrollment. As evidenced by reductions in LGA birth 
weight and neonatal fat mass, infants of women classified as overweight, Class I, or Class II 
obese clearly benefited from formal nutritional counseling, diet therapy, and daily glucose 
monitoring. However, normal weight and morbidly obese women who were treated did not 
demonstrate similar significant reductions in these outcomes. Importantly, umbilical cord 
serum c-peptide (fetal hyperinsulinemia) did not appear to be related to maternal BMI.
In the latest Centers for Disease Control and Prevention report, approximately 56.7% of 
women of reproductive age were determined to be at least overweight. The prevalence of 
obesity was 30.2 %.18 The number of overweight and obese women at enrollment in the 
GDM study was remarkably higher (85%). This is not surprising when one considers that 
the pathophysiology of GDM is intimately linked to maternal obesity. However, the 
differential contribution of maternal obesity and maternal hyperglycemia to outcomes 
frequently associated with diabetes (i.e. LGA birth weight) is not easily sorted out. In a 
recent analysis of more than 23,000 women enrolled in the HAPO study, the likelihood of 
delivering an LGA infant was almost 5 times higher in women who were considered 
overweight or obese.5 After adjustment for fasting maternal glucose levels and numerous 
other maternal and fetal characteristics, there was a persistent 3-fold increased risk for LGA 
birth weight for the same BMI categories. The idea that maternal obesity is a more 
significant risk factor for delivery of an LGA infant when compared to maternal glucose 
intolerance has been reported in the past.3,4,19,20
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The complex process of fetal growth is largely determined by transfer of nutrients across the 
placenta and is dependent on several factors, including maternal nutrient levels, maternal 
hormone levels, placental size and blood flow, and placental nutrient transporters. Together, 
these genetic and environmental factors can modify and differentially affect fetal growth.21 
It is also widely held that in pregnancies complicated by diabetes, maternal hyperglycemia 
leads to fetal hyperinsulinemia and subsequent fetal overgrowth.22 This simple view 
however, does not explain the persistent increased risk of LGA infants in women with GDM 
who demonstrate good glycemic control.23 Along these lines, we were unable to 
demonstrate a significant reduction in LGA birth weight or neonatal fat mass in morbidly 
obese women treated for mild GDM. One explanation for these findings is that factors other 
than maternal hyperglycemia contribute to excess fetal growth in these cases. For example, 
maternal obesity has been linked with low-grade inflammation that leads to a shift in 
commitment of fetal mesenchymal cells from myogenesis to adipogenesis.24 This initial 
change in the properties of fetal muscle cells in offspring of obese mothers may lead to a 
cascade of events that is first recognized as excessive fetal size regardless of glucose 
tolerance or control. Alterations in expression of genes related to fetoplacental lipid 
homeostasis in obese women with GDM is another plausible mechanism for fetal 
overgrowth unrelated to maternal glycemia.25 Therefore, we believe that the lack of 
demonstrable treatment benefit in morbidly obese women indicate that there may be a limit 
to improvements achievable through interventions directed toward maternal glucose levels 
alone.
Similar to our findings in morbidly obese women, we were unable to reduce infant LGA 
birth weight or neonatal fat mass with nutritional counseling and diet therapy in 143 normal 
weight women with mild GDM. Actually, treated women had higher rates of both outcomes. 
When considering potential opportunities for improved outcomes in such women however, 
it is important to acknowledge that the number of overgrown infants delivered to such 
women is relatively small. In fact there were only 3 (2%) LGA infants delivered in this 
normal weight cohort. For comparison, one large population study of over 146,000 births, 
including women with diabetes, reported the rate of LGA birth weight in normal women as 
8.7% in contrast to 16.4% in obese women.26 Classification of body composition for our 
study was based on weight at the time of enrollment and this could be one reason the 
absolute LGA rate was lower in these normal weight women with mild GDM. Nonetheless, 
we are of the view that the lack of benefit in these women suggests that there may be limited 
opportunity for improvement in outcomes in normal weight women with mild GDM. 
Indeed, current screening recommendations from the Fifth International Workshop-
Conference on Gestational Diabetes Mellitus exclude normal weight women from a risk-
based, selective screening approach.27 To further illustrate this point, based on the data now 
reported, we estimate that over 5,000 normal weight women with mild GDM would have to 
be randomized in order to determine if treatment was beneficial in this subgroup. Over the 
span of 5 years, the MFMU Network identified and randomized 143 normal weight women 
to treatment, making such a study in normal weight women not feasible.13
Our findings of diminished treatment effect on fetal growth at the extremes of maternal body 
composition should be viewed with caution. First, given that this study was performed in 
women with only mild degrees of glucose intolerance, the potential absolute risk reduction 
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for fetal overgrowth is smaller.23 There were also very few randomized women who were 
considered morbidly obese. This is true despite the fact that women were classified 
according to weight at enrollment and this is plausibly overestimated. While the finding of 
no difference in LGA birthweight in morbidly obese women may arguably be related to 
these small numbers, we believe the lack of any reduction associated with treatment 
suggests a limitation to diet therapy in these women. Another potential weakness of this 
study is that we did not consider weight gain during pregnancy. However, in women 
weighing more than 135% of ideal body weight for height, it has been reported that there is 
no correlation between weight gain and birth weight.28 Despite these shortcomings, it seems 
apparent that diabetes-related fetal overgrowth is a marginal problem in normal weight 
women identified with mild GDM and that excess fetal growth in morbidly obese women 
with GDM cannot be simply addressed with interventions aimed at maternal glucose control. 
It also seems unlikely that a randomized trial addressing these subgroups of women with 
GDM is feasible. With consideration of the less stringent criteria for the diagnosis of GDM 
currently proposed by the IADPSG and the associated disproportionate increase in the 
number of women with mild GDM, we believe our findings could help guide resource 
allocation or therapeutic interventions and moderate expectations for treatment benefit in 
women with GDM at the extremes of BMI. 11
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Percent LGA according to maternal body mass index (BMI) and treatment group in women 
with mild gestational diabetes who were randomized to either diet therapy and glucose 
monitoring or routine prenatal care. The X2 or Fisher exact test was used to compare 
treatment groups within BMI category.
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Neonatal Fat Mass (grams) according to maternal body mass index (BMI) and treatment 
group in women with mild gestational diabetes that were randomized to either diet therapy 
and glucose monitoring or routine prenatal care. The Wilcoxon rank sum test was used to 
compare treatment groups within BMI category.
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Table 1
Baseline maternal characteristics of 958 women identified with mild gestational diabetes and randomized to 





n = 473 p-value
Age, yrs 29 ± 5.1 29 ± 5.6 0.86
Primigravida 104 (21) 123 (26) 0.10
Race 0.55
Black 56 (12) 54 (12)
White 123 (25) 119 (25)
Hispanic 281 (58) 265 (56)
Other 25 (5) 35 (7)
Gestational age at randomization, wks 29 ± 0.6 29 ± 1.5 0.13
BMI category, kg/m2 1.0
Normal weight (< 25) 73 (15) 70 (15)
Overweight (25 – 29.9) 187 (38) 181 (38)
Class I Obese (30 – 34.9) 153 (32) 151 (32)
Class II Obese (35 – 39.9) 53 (11) 57 (11)
Class III Obese (≥ 40) 19 (4) 20 (4)
50 mg challenge, mg% 159 ± 15.3 160 ± 15.5 0.50
100 gm test:
Fasting, mg% 87 ± 5.7 86 ± 5.7 0.34
1 hr, mg % 192 ± 21.9 193 ± 19.3 0.11
2 hr, mg% 174 ± 21.8 173 ± 19.6 0.84
3 hr, mg% 137 ± 29.0 134 ± 31.5 0.14
Data presented as n(%) or mean ± SD.
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